Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486233 | 0.83 | PKM (0.37) | ALDH1A1KDRCDK8CDK5DYRK1A | |
| SCHEMBL4481644 | 0.82 | KDR (0.43) | GSK3BGSK3AKDRCDK8MAPT | |
| SCHEMBL4481101 | 0.82 | ALDH1A1 (0.46) | CYP1A2TP53ALDH1A1MEN1KMT2A | |
| SCHEMBL4485740 | 0.75 | CAMKK2 (0.35) | GSK3BGSK3AKDRCDC7DAPK3 | |
| SCHEMBL4477424 | 0.75 | RIPK1 (0.51) | GSK3BGSK3AKDRDAPK3ROCK2 | |
| SCHEMBL4471715 | 0.69 | SMN1; SMN2 (0.51) | ALDH1A1MEN1KMT2AHPGDMAPT | |
| SCHEMBL4479411 | 0.68 | MAP3K11 (0.48) | ALDH1A1ROCK2CDK5DYRK1ALRRK2 | |
| SCHEMBL4470289 | 0.68 | POLB (0.43) | GSK3BCYP1A2ALDH1A1MEN1POLB | |
| SCHEMBL1709756 | 0.68 | TP53 (0.72) | TP53ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL4491792 | 0.68 | MEN1 (0.57) | MEN1POLBKMT2AKDRROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592365-B2 | Substituted pyrroles, compositions containing same, method for making same and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-09-22 | — | — | US | disclosed |
| EP-1851198-B1 | SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2008-12-31 | — | — | EP | disclosed |
| US-20080167368-A1 | Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-07-10 | — | — | US | disclosed |
| EP-1851198-A1 | SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006084996-A1 | SUBSTITUTED PYRROLES, COMPOSITIONS CONTAINING SAME, METHOD FOR MAKING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167368-A1 | Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof | PRMT1, ADPRS, RRM2B | GSK3B 4092/4885CYP1A2 1308/4885TP53 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.